Quick Answer
HALOZYME THERAPEUTICS, INC. reported Long-Term Debt of $2.14 billion for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $2.14B | +42.3% |
| 2024 | $1.51B | +0.4% |
| 2023 | $1.50B | +0.4% |
| 2022 | $1.49B | +89.6% |
| 2021 | $787.25M | — |
| 2020 | $0.00 | -100.0% |
| 2019 | $383.05M | +998.4% |
| 2018 | $34.87M | -72.1% |
| 2017 | $125.14M | -37.2% |
| 2016 | $199.23M | +612.3% |
| 2015 | $27.97M | -43.9% |
| 2014 | $49.86M | +0.2% |
| 2013 | $49.77M | +67.8% |
| 2012 | $29.66M | — |
| 2011 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $800.07M | -46.8% | -47.0% |
| June 30, 2025 | $1.51B | +0.4% | +0.1% |
| March 31, 2025 | $1.51B | +0.4% | +0.1% |
| December 31, 2024 | $1.51B | +0.4% | +0.1% |
| September 30, 2024 | $1.50B | +0.4% | +0.1% |
| June 30, 2024 | $1.50B | +0.4% | +0.1% |
| March 31, 2024 | $1.50B | +0.4% | +0.1% |
| December 31, 2023 | $1.50B | +0.4% | +0.1% |
- HALOZYME THERAPEUTICS, INC. showed an increase of +42.3% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: